Current and future trends of [18F]FDG PET/CT in pediatric Hodgkin lymphoma.
1/5 보강
[F]FDG PET/CT plays a pivotal role in the contemporary management of malignant lymphoma, and is crucial for accurate staging, response assessment, and treatment planning in pediatric Hodgkin lymphoma
APA
Linguanti F, Abenavoli E, et al. (2025). Current and future trends of [18F]FDG PET/CT in pediatric Hodgkin lymphoma.. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 69(4), 298-307. https://doi.org/10.23736/S1824-4785.25.03679-9
MLA
Linguanti F, et al.. "Current and future trends of [18F]FDG PET/CT in pediatric Hodgkin lymphoma.." The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., vol. 69, no. 4, 2025, pp. 298-307.
PMID
41148576 ↗
Abstract 한글 요약
[F]FDG PET/CT plays a pivotal role in the contemporary management of malignant lymphoma, and is crucial for accurate staging, response assessment, and treatment planning in pediatric Hodgkin lymphoma (pHL). Treatment response evaluation in pHL and in particular interim [F]FDG PET/CT done after few cycles of chemotherapy is critical for early prediction of outcome. It helps in identifying patients who would respond well and might safely omit radiotherapy, thereby reducing the risk of late adverse effects. Consequently, consensus international guidelines emphasize the standardized use of [F]FDG PET/CT in pHL, thus facilitating comparison of clinical trial outcomes and optimizing individualized patient care worldwide. In the present review we aim to summarize essential aspects of [F]FDG PET/CT in pHL, by providing new approaches and future developments.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.